glaxosmithkline plc-spon adr
(GSK:New York Consolidated)
Transactions by GLAXOSMITHKLINE PLC-SPON ADR (GSK) in the last 6 months
GlaxoSmithKline plc (LSE:GSK) entered into an agreement to acquire 25% stake in Aspen Japan K.K. from Aspen Global Incorporated on October 9, 2014. Completion of the agreement is subject to a number of conditions precedent one of which is Aspen Japan K.K. obtaining accreditation as a marketing authorisation holder from the relevant Japanese regulatory authority. The transaction is expected to close by the end of 2015. Richard Smith, Jeremy Chew, Claire Jackson, Susie ...
Silarus Therapeutics, Inc. announced that it will receive $10 million in its series A round of funding from new investors Avalon Ventures, LLC and GlaxoSmithKline plc on September 22, 2014. The investors will acquire majority stake in the company.
|3M Co||$159.36 USD||+0.53|
|AbbVie Inc||$65.19 USD||-0.31|
|Bayer AG||€113.84 EUR||+0.125|
|Celgene Corp||$107.35 USD||+0.37|
|Novo Nordisk A/S||kr263.80 DKK||-0.70|
|View Industry Companies|